Source: Annual Congress 2009 - Management of thoracic malignancies



Rating:

Share or cite this content

Citations should be made in the following way:
E. Eleftheriadou, G. Gerasimou, P. Zarogoulidis, C. Gioka, G. Balassoulis, I. Sapardanis, T. Kontakiotis, A. Gotzamani-Psarrakou, N. Karatzas, K. Zarogoulidis (Exohi, Thessaloniki, Thessaloniki, Greece). The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings). Eur Respir J 2009; 34: Suppl. 53, 2621

Member's Comments

No comment yet.

Related content which might interest you: The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 The effect of anti-tuberculosis chemotherapy using second-line drugs on the structural and functional state of the thyroid gland Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Potential role of antidepressants as part of anticancer therapy Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 The possibility of strengthening of activity of antituberculous drugs: preliminary results Source: Annual Congress 2004 - Management of tuberculosis Year: 2004 Relapsed NSCLC and SCLC: benefits and limitations of systemic treatments beyond the second line Source: International Congress 2017 – Rational strategies for specific treatment situations in lung cancer Year: 2017 A preliminary study on targeted therapies in advanced lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008